Chimeric inhibitor molecules of complement activation
US-9815876-B2 · Nov 14, 2017 · US
Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
US8933201B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8933201-B2 |
| Application number | US-96916110-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 15, 2010 |
| Priority date | Jun 7, 2006 |
| Publication date | Jan 13, 2015 |
| Grant date | Jan 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α 2 -antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma α 2 -antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having the formula: B-Xaa 1 -Sp-Xaa 2 -Cyc (Formula I) wherein: B is at least one of acetyl, pyroglutamate, and succinyl; Xaa 1 is a positively-charged amino-acid; Sp is a spacer molecule having a length in the range of 0.3 nm to 2.5 nm; Xaa 2 is glycine, D-alanine, D-serine, or D-threonine; and Cyc is boronyl proline or cyanopyrrolidine; and wherein the compound binds to the active site of Antiplasmin Cleaving Enzyme (APCE) a…
Assignees
Inventors
Classifications
- C07K14/8121Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
- C07K5/06026Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8933201B2 cover?
- The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α 2 -antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, …
- Who is the assignee on this patent?
- Mckee Patrick A, Jackson Kenneth W, Lee Kyung N, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/8121. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).